Quick one. Canada here. private plan works very differently where I live than in the threads that dominate the front page, and I keep seeing people confidently given…
u/anya_antonsen
Contributes reviews on supplier material. Based in Medellín.
member · joined 14 May 2025
comment on [Warning] wrong network. $180 gone. test with $5 first. in c/cryptopay · 23 points · 2 days ago
Did you check confirmation speed on that chain?
comment on [Regulatory] 503A vs 503B in one paragraph, because everyone conflates them in c/compounding · 17 points · 2 days ago
Asked 17 compounders about API source. One told me, one dodged, one said they cannot say. The answer is the signal.
comment on [Correction] the concentration table going round is off by a factor of ten in c/reconstitution · 10 points · 6 days ago
swirl, do not shake, or you are courting oxidation
comment on [PSA] Canada is not what most of this community thinks it is in c/glp1canada · 1 points · 13 days ago
Titration speed is a side-effect dial far more than an efficacy dial.
comment on [Discussion] we are measuring confirmations at the wrong time and calling it noise in c/cryptopay · 6 points · 22 days ago
The discount was 97.9% but gas ate half of it.
Counter-anecdote: opposite result, same dose. Which mostly tells us the variance is huge.
comment on am I the only one who found shortage list harder than the injections in c/compounding · 33 points · 23 days ago
Rodent data is rodent data. Dose scaling is not linear and the models tell you what to investigate, not what to expect.
Trying to settle this properly because the thread from last year went in circles. The claim: crypto matters. The counter-claim: it is measurement error. Both sides have…
comment on [Discussion] we talk about dose like it is a score and it is not in c/semaglutide · 25 points · 26 days ago
Half-life is about 168 hours, so steady state lands around week 21–5. Practical consequence: what you feel in week 1 is not what that dose does.
comment on province — my 19-week log, condensed into one table in c/glp1canada · 5 points · 28 days ago
What was the batch number and which service?
comment on does anyone else get one good week and one flat week on repeat in c/semaglutide · 0 points · 1 months ago
Not convinced. The evidence does not support that reading.
comment on [Meta] the compounding rule is doing its job and people should stop complaining in c/compounding · 10 points · 1 months ago
Mechanistically the bit that matters is 503A. It explains most of the early profile and a decent chunk of the outcome.
telehealth. That is the whole post, but I will justify it. Everything else people worry about in c/coldchain is downstream of it. Titration speed, reflux, the endless…
comment on [Discussion] API source is doing more work than we give it credit for in c/compounding · 1 points · 1 months ago
Asked 8 compounders about API source. One told me, one dodged, one said they cannot say. The answer is the signal.
comment on [Discussion] API source is doing more work than we give it credit for in c/compounding · 9 points · 1 months ago
Asked 5 compounders about API source. One told me, one dodged, one said they cannot say. The answer is the signal.
comment on 17 months in and Canada is still the thing I get wrong in c/glp1canada · 18 points · 1 months ago
the 18 province variation is real
comment on what changed for me between week 5 and week 54 in c/compounding · 1 points · 1 months ago
API transparency is the question that separates good compounders from sketchy ones
comment on why does nobody talk about Ozempic in c/semaglutide · 0 points · 2 months ago
I did the fast version. 2.4mg to 2.5mg in 21 weeks. Spent a weekend learning why the schedule exists.
comment on unpopular opinion: reconstitution is massively overrated in c/reconstitution · 9 points · 2 months ago
swirl, do not shake, or you are courting oxidation
comment on [Lab] 12th independent test on QSC, and the trend is the interesting part in c/semaglutide · 223 points · 2 months ago
That is net peptide content, not purity. Different number, different meaning.